Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.

2.

Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.

McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01576-17. doi: 10.1128/AAC.01576-17. Print 2018 Feb.

3.

Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Papp-Wallace KM, Senkfor B, Gatta J, Chai W, Taracila MA, Shanmugasundaram V, Han S, Zaniewski RP, Lacey BM, Tomaras AP, Skalweit MJ, Harris ME, Rice LB, Buynak JD, Bonomo RA.

Antimicrob Agents Chemother. 2012 Nov;56(11):5687-92. doi: 10.1128/AAC.01027-12. Epub 2012 Aug 20.

4.
5.

In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.

Deveci A, Coban AY, Acicbe O, Tanyel E, Yaman G, Durupinar B.

J Chemother. 2012 Oct;24(5):247-52. doi: 10.1179/1973947812Y.0000000029.

PMID:
23182043
6.

Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.

Chiu CH, Lee HY, Tseng LY, Chen CL, Chia JH, Su LH, Liu SY.

Int J Antimicrob Agents. 2010 Apr;35(4):382-6. doi: 10.1016/j.ijantimicag.2009.12.009. Epub 2010 Feb 6.

PMID:
20138741
7.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA.

Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.

PMID:
28665414
8.

In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

Housman ST, Hagihara M, Nicolau DP, Kuti JL.

J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.

PMID:
23710070
9.
10.

Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii.

Choi JY, Park YS, Cho CH, Park YS, Shin SY, Song YG, Yong D, Lee K, Kim JM.

Clin Microbiol Infect. 2004 Dec;10(12):1098-101.

11.

Molecular Epidemiology and Mechanism of Sulbactam Resistance in Acinetobacter baumannii Isolates with Diverse Genetic Backgrounds in China.

Yang Y, Fu Y, Lan P, Xu Q, Jiang Y, Chen Y, Ruan Z, Ji S, Hua X, Yu Y.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01947-17. doi: 10.1128/AAC.01947-17. Print 2018 Mar.

12.

In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.

Liu B, Bai Y, Liu Y, Di X, Zhang X, Wang R, Wang J.

J Chemother. 2015 Oct;27(5):271-6. doi: 10.1179/1973947814Y.0000000203. Epub 2014 Jul 28.

PMID:
25068186
13.

In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.

Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M.

J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.

PMID:
24265334
14.

Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii.

Temocin F, Erdinc FS, Tulek N, Demirelli M, Ertem G, Kinikli S, Koksal E.

Braz J Microbiol. 2015 Oct-Dec;46(4):1119-24. doi: 10.1590/S1517-838246420140101.

15.

In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.

Punpanich W, Munsrichoom A, Srisarang S, Treeratweeraphong V.

J Med Assoc Thai. 2011 Aug;94 Suppl 3:S95-100.

PMID:
22043760
16.

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.

J Antimicrob Chemother. 2007 Aug;60(2):317-22. Epub 2007 May 31.

PMID:
17540672
17.
18.

TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii.

Krizova L, Poirel L, Nordmann P, Nemec A.

J Antimicrob Chemother. 2013 Dec;68(12):2786-91. doi: 10.1093/jac/dkt275. Epub 2013 Jul 9.

PMID:
23838947
19.

In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.

Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, Turner PJ, Mendes C.

Diagn Microbiol Infect Dis. 2005 Aug;52(4):317-22.

PMID:
15936166
20.

Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.

Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, Pachón J, Pascual A.

J Antimicrob Chemother. 2006 Sep;58(3):689-92. Epub 2006 Jul 26.

PMID:
16870647

Supplemental Content

Support Center